Physician profile
Asma Haydar
NPI 1386236909
$1,477.45
in general payments reported to CMS, 2019-2025
21 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.59 · 2022: $666 · 2023: $229 · 2024: $284 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $246.66 | 2022-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $165.65 | 2022-2023 | |
| Antares Pharma, INC. | $140.43 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Lilly USA, LLC | $127.23 | 2022-2024 | Mounjaro, Zepbound |
| Vertex Pharmaceuticals Incorporated | $124.74 | 2025 | |
| Medtronic, INC. | $107.39 | 2022 | |
| Amgen INC. | $79.59 | 2022-2024 | Tepezza, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $77.25 | 2022-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $75.50 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.13 | 2024-2025 | Caplyta |
| Dexcom, INC. | $45.87 | 2022-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $38.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.48 | 2022 | |
| Nevro Corp. | $34.83 | 2022 | |
| Axsome Therapeutics, INC. | $33.21 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.42 | 2024 | |
| Xeris Pharmaceuticals, INC. | $16.35 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.64 | 2023 | Unithroid |
| Exact Sciences Corporation | $13.56 | 2024 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $12.11 | 2022 | |
| Currax Pharmaceuticals LLC | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Haydar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.